Cambrex Co. (NYSE:CBM) has been assigned a consensus rating of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $60.50.
A number of analysts have weighed in on the company. Zacks Investment Research raised Cambrex from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. William Blair started coverage on Cambrex in a research note on Tuesday, January 16th. They issued an “outperform” rating on the stock. Finally, Craig Hallum reiterated a “buy” rating and issued a $60.00 price objective (down from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st.
Shares of Cambrex (NYSE:CBM) opened at $56.35 on Tuesday. Cambrex has a 12-month low of $42.55 and a 12-month high of $62.95. The firm has a market capitalization of $1,840.00, a PE ratio of 18.48, a price-to-earnings-growth ratio of 1.34 and a beta of 2.26.
Institutional investors have recently bought and sold shares of the company. Stifel Financial Corp increased its stake in shares of Cambrex by 0.8% in the second quarter. Stifel Financial Corp now owns 4,580 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 37 shares during the period. Piedmont Investment Advisors LLC bought a new position in shares of Cambrex in the second quarter worth about $421,000. Tributary Capital Management LLC increased its stake in shares of Cambrex by 22.3% in the third quarter. Tributary Capital Management LLC now owns 232,919 shares of the biotechnology company’s stock worth $12,811,000 after purchasing an additional 42,428 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Cambrex by 117.0% in the third quarter. JPMorgan Chase & Co. now owns 231,931 shares of the biotechnology company’s stock worth $12,721,000 after purchasing an additional 125,062 shares during the period. Finally, California Public Employees Retirement System increased its stake in shares of Cambrex by 4.4% in the second quarter. California Public Employees Retirement System now owns 73,500 shares of the biotechnology company’s stock worth $4,392,000 after purchasing an additional 3,100 shares during the period.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/23/cambrex-co-cbm-receives-average-recommendation-of-hold-from-brokerages.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.